
# **Investor Update**





# Reminder: Invitation to Roche's Virtual Neurology Investor Event

We are pleased to invite investors and analysts to participate in our virtual event on **Friday, 4 April 2025**, to highlight new results from Roche's Neurology pipeline including Phase III (EMBARK) Elevidys in DMD 2-year data presented at the Muscular Dystrophy Association conference (MDA) from 16-19 March 2025, as well as Phase IIb (PADOVA) data for prasinezumab in PD and Phase Ib/II (Brainshuttle™) data for trontinemab in AD presented at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025) from 1-5 April 2025.

16:00 - 17:30 CEST / 15:00 - 16:30 BST 10:00 - 11:30 am EDT / 7:00 - 8:30 am PDT

The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 15:00 CEST on the day of the event. > click here

# **Agenda**

#### Introduction

Bruno Eschli, Head of Investor Relations

# **Neurology Update**

Azad Bonni, SVP and Global Head of Neuroscience & Rare Diseases, Roche Pharma Research & Early Development

## Prasinezumab in Parkinson's disease: Ph IIb PADOVA data

Azad Bonni, SVP and Global Head of Neuroscience & Rare Diseases, Roche Pharma Research & Early Development

# Trontinemab in Alzheimer's disease: Ph Ib/II Brainshuttle™ data

Luka Kulic, VP and Global Head of Early Development, Neuroscience & Rare Diseases, Roche Pharma Research & Early Development

# Elevidys in Duchenne Muscular Dystrophy: Ph III EMBARK 2 yr data presented at MDA

Alex Murphy, Senior Clinical Director, Neuromuscular Disorders & Stroke, Roche

#### Q&A

## Access to virtual event (pre-registration required)

Please pre-register for our webinar <u>here\*</u>.

Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to <a href="mailto:investor.relations@roche.com">investor.relations@roche.com</a>.

A replay of the webcast will be available via > ir.roche.com

#### \*privacy notice

Best regards,

Bruno Eschli

**Head of Investor Relations** 

Sabine Borngräber

**Investor Relations Officer** 

## **Roche Investor Relations**

Dr. Bruno Eschli

Phone: +41 61 68-75284

e-mail: bruno.eschli@roche.com

Dr. Sabine Borngräber

Phone: +41 61 68-88027

e-mail: <a href="mailto:sabine.borngraeber@roche.com">sabine.borngraeber@roche.com</a>

Dr. Birgit Masjost

Phone: +41 61 68-84814

e-mail: birgit.masjost@roche.com

# **Investor Relations North America**

# Loren Kalm

Phone: +1 650 225 3217

e-mail: kalm.loren@gene.com